Practical Guidance for the Use of Patisiran in the Management of Polyneuropathy in Hereditary Transthyretin-Mediated Amyloidosis by Dixon S, Kang X, Quan D

Subjects: “…patisiran…”
Get full text

A real-world pharmacovigilance analysis for transthyretin inhibitors: findings from the FDA adverse event reporting database by Yuan Liu, Hao Li, Cheng Hu, Li Tan, Ping Yin, Zhihao Li, Shuangshan Zhou, Li Su

Subjects: “…patisiran…”
Get full text

A phase II, open-label, extension study of long-term patisiran treatment in patients with hereditary transthyretin-mediated (hATTR) amyloidosis by Teresa Coelho, David Adams, Isabel Conceição, Márcia Waddington-Cruz, Hartmut H. Schmidt, Juan Buades, Josep Campistol, John L. Berk, Michael Polydefkis, Jing Jing Wang, Jihong Chen, Marianne T. Sweetser, Jared Gollob, Ole B. Suhr

Subjects: Get full text

Treatment characteristics of patients with hereditary transthyretin amyloidosis: a cohort study by Taha N. Qarni, Felipe J. S. Jones, Brian Drachman, Sami Khella, Janice Pieretti, Nicolas Sarmiento Bustamante, Chafic Karam

Subjects: Get full text

A Comparison of Currently Approved Small Interfering RNA (siRNA) Medications to Alternative Treatments by Costs, Indications, and Medicaid Coverage by Inder Sehgal, Kevin Eells, Imani Hudson

Subjects: Get full text

Navigating the Complex Web of Prescribing Amyloidosis Therapeutics: A Primer by Hongya Chen, Pranav Chandrashekar, Katherine Fischer, Dayna Carlson, Urja Narayan, Jack Chen, Ahmad Masri

Subjects: Get full text

Advances in the treatment of hereditary transthyretin amyloidosis: A review by Morie A. Gertz, Michelle L. Mauermann, Martha Grogan, Teresa Coelho

Subjects: Get full text

Italian Real-Life Experience of Patients with Hereditary Transthyretin Amyloidosis Treated with Patisiran by Di Stefano V, Fava A, Gentile L, Guaraldi P, Leonardi L, Poli L, Tagliapietra M, Vastola M, Fanara S, Ferrero B, Giorgi M, Perfetto F, Russo M, Russo D

Subjects: Get full text

Assessing the effectiveness and safety of Patisiran and Vutrisiran in ATTRv amyloidosis with polyneuropathy: a systematic review by Mohammad Amin Karimi, Fatemeh Esmaeilpour Moallem, Mohammad Sadra Gholami Chahkand, Eftekhar Azarm, Mohammad Javad Emami Kazemabad, Parisa Alsadat Dadkhah

Subjects: Get full text

A novel TTR mutation (p.Ala65Val) underlying late-onset hereditary transthyretin (ATTRv) amyloidosis with mixed cardiac and neuropathic phenotype: a case report by Andreas Thimm, Sara Oubari, Julia Hoffmann, Alexander Carpinteiro, Maria Papathanasiou, Peter Luedike, Lukas Kessler, Christoph Rischpler, Christoph Röcken, Isabel Diebold, Tienush Rassaf, Hartmut Schmidt, Christoph Kleinschnitz, Tim Hagenacker

Subjects: Get full text

Update on the clinical utility of an RNA interference-based treatment: focus on Patisiran by Rizk M, Tüzmen S

Subjects: Get full text

Trial design and rationale for APOLLO, a Phase 3, placebo-controlled study of patisiran in patients with hereditary ATTR amyloidosis with polyneuropathy by David Adams, Ole B. Suhr, Peter J. Dyck, William J. Litchy, Raina G. Leahy, Jihong Chen, Jared Gollob, Teresa Coelho

Subjects: “…Patisiran…”
Get full text

2018 FDA Tides Harvest by Danah Al Shaer, Othman Al Musaimi, Fernando Albericio, Beatriz G. de la Torre

Subjects: Get full text

Patisiran Enhances Muscle Mass after Nine Months of Treatment in ATTRv Amyloidosis: A Study with Bioelectrical Impedance Analysis and Handgrip Strength by Vincenzo Di Stefano, Ewan Thomas, Paolo Alonge, Valerio Giustino, Guglielmo Pillitteri, Ignazio Leale, Angelo Torrente, Antonia Pignolo, Davide Norata, Salvatore Iacono, Antonino Lupica, Antonio Palma, Giuseppe Battaglia, Filippo Brighina

Subjects: Get full text

A comparative analysis of international health technology assessments for novel gene silencing therapies: patisiran and inotersen by Sergio Iannazzo

Subjects: Get full text

Successful Treatment with Patisiran in Amyloid Polyneuropathy Harboring His90Asn Mutation in the <i>TTR</i> Gene by Vincenzo Di Stefano, Pietro Guaraldi, Francesca Giglia, Ilaria Cani, Antonia Pignolo, Luca Codeluppi, Paolo Alonge, Elena Canali, Giovanni De Lisi, Ada Maria Florena, Eugenia Borgione, Filippo Brighina

Subjects: Get full text

Patisiran, an RNAi therapeutic for hereditary transthyretin-mediated amyloidosis: Sub-analysis in Taiwanese patients from the APOLLO study by Kon-Ping Lin, Chih-Chao Yang, Yi-Chung Lee, Ming-Jen Lee, John Vest, Marianne T. Sweetser, Matthew T. White, Prajakta Badri, Sung-Tsang Hsieh, Chi-Chao Chao

Subjects: Get full text

Patisiran for the treatment of patients with p.Ile88Leu hereditary transthyretin amyloidosis: an Italian real-life experience by Giacomo Urbinati, Ilaria Cani, Marco Currò Dossi, Simone Longhi, Samuela Carigi, Christian Gagliardi, Elena Biagini, Nazzareno Galiè, Pietro Cortelli, Pietro Cortelli, Pietro Guaraldi

Subjects: Get full text